ArticleFrontiers in oncology2024
Solid pseudopapillary neoplasm of the pancreas: a retrospective study of 195 cases.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Diagnostic algorithm for the imaging evaluation of a solid pancreatic mass: is it malignant?Abdominal radiology (New York) · 2026Review
- Solid pseudopapillary neoplasm of the pancreas with postoperative multiple liver metastases in an older woman: a case report.Journal of gastrointestinal oncology · 2026Article
- Article
- Tailored Surgical Treatment and Outcomes in Solid Pseudopapillary Neoplasms of the Pancreas: A Case Series of Five Consecutive Paradigmatic Cases.Diseases (Basel, Switzerland) · 2026Article
- Giant solid pseudopapillary neoplasm of the pancreas in an adolescent girl: a case report with narrative review.Frontiers in oncology · 2026Article
- APC-rearranged solid pseudopapillary neoplasm-pancreatic neuroendocrine tumor collision tumor: a molecularly resolved case report.Frontiers in oncology · 2026Article
- The nomograph predicting the recurrence of Solid Pseudopapillary Neoplasm of the Pancreas: a study of the SEER database and a Chinese cohort.BMC gastroenterology · 2025Article
- High-Risk Pregnancy with Solid Pseudopapillary Tumor of the Pancreas Complicated by Obstetric Antiphospholipid Syndrome: A Case Report.International journal of women's health · 2025Article
- Ruptured solid pseudopapillary neoplasm in children: a 20-year single-center experience.Frontiers in pediatrics · 2025Article
- [Solid Pseudopapillary Neoplasm of the Pancreas: Diagnosis and Surgical Management in a Young Patient].Acta gastroenterologica LatinoamericanaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare exocrine tumor of the pancreas. The aim of our study is to summarize the clinical features of SPN and to analyze the risk factors for malignant SPN. Methods: From May 2013 to September 2022, patients who were pathologically confirmed to have SPN were retrospectively reviewed. Demographic data, clinical and pathological features, follow-up data were collected and analyzed. To investigate the factors influencing the benign or malignant nature of SPN, we employed logistic regression. Additionally, we utilized Kaplan-Meier curves to depict and analyze the overall prognosis. Results: A total of 195 patients were included, 163 of whom were female and the average age of all patients was 31.7 years old. Among 195 patients, 101 patients (51.8%) had no obvious clinical symptoms and their pancreatic lesions were detected during routine examination. The primary symptom was abdominal pain and distension in 64 cases (32.8%). The maximum diameter of SPN tumors ranged from 1-17 cm (mean 6.19 cm). Forty-eight postoperative complications developed in 43 (22.1%) patients. After a median follow-up duration of 44.5 months, the overall 5-year survival rate was 98.8% and the recurrence rate was 1.5%. Furthermore, we observed a statistically significant difference in the completeness of the tumor capsule between benign and malignant SPN. Conclusion: SPN is associated with a favorable long-term survival after surgery in our large sample size cohort. For malignant SPN, tumor capsule incompleteness is an independent risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.